Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 24:10:1-5.
doi: 10.2147/BLCTT.S262592. eCollection 2020.

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Chaitra Ujjani  1 , Anthony Mato  2 , Brian T Hill  3 , John N Allan  4 , Frederick Lansigan  5 , Ryan Jacobs  6 , Alan Skarbnik  7 , Hande Tuncer  8 , John Pagel  9 , Danielle Brander  10 , Bruce Cheson  11 , Paul Barr  12 , Lindsey E Roeker  2 , Jeffrey Pu  13 , Nirav N Shah  14 , Andre Goy  15 , Stephen J Schuster  16 , Nicole Lamanna  17 , Alison Sehgal  18 , Constantine S Tam  19 , Mazyar Shadman  1
Affiliations

The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

Chaitra Ujjani et al. Blood Lymphat Cancer. .

Abstract

Introduction: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years compared to ECOG 1912, which included patients up to 70 years of age.

Methods: Therefore, we conducted a retrospective analysis to investigate whether ibrutinib was associated with a greater mortality in older patients outside of a clinical trial setting. This multicenter analysis was performed by investigators at 20 academic and community practices.

Results: Amongst the 391 patients included, there was no correlation between age and response rate, PFS, or OS. However, there was a trend to higher rate of deaths in patients >65-years-old (8.7% vs 3.8%, p=0.097), with an increased number of early deaths (13 vs 4, p=0.3).

Conclusion: These data suggest greater intolerance, and possibly mortality, with ibrutinib in an older population. Patients should be educated regarding the potential complications related to ibrutinib and symptoms of concern to report.

Keywords: CLL; elderly; ibrutinib.

PubMed Disclaimer

Conflict of interest statement

Chaitra Ujjani reports non-financial supports from Pharmacyclics, Abbvie, Genentech, AstraZeneca, and Verastem. Anthony Mato reports grants and personal fees from TG Therapeutics, Celgene, Abbvie, Loxo, Sunesis, Genentech, DTRM, AstraZeneca, Octopharma, Janssen, Regeneron, Adaptive, and Pharmacyclics. Brian T Hill reports grants, personal fees from Pharmacyclics, Abbvie, AstraZeneca. John N Allan reports personal fees from Abbvie, Janssen, Pharmacyclics, Genentech, TG Therapeutics, Verastem, Sunesis, and Ascentage Pharma Group. Frederick Lansigan reports consulting fees from Acrotech and is part of the steering committee for Celgene. Alan Skarbnik is a consultant for Janssen, Pharmacyclics, Abbvie, Celgene, Kite, Alexion, Jazz Pharmaceuticals, and AstraZeneca and received payments for lectures including service on speakers bureaus from Janssen, Pharmacyclics, Abbvie, Celgene, Kite, Alexion, Jazz Pharmaceuticals, AstraZeneca, Beigene, Seattle Genetics, Genentech, and Verastem. Ryan Jacobs reports grants and/or personal fees from Pharmacyclics, Genentech, Abbvie, Verastem, TG Therapeutics, Janssen, Astra Zeneca. John Pagel reports personal fees from Gilead, Beigene, Loxo, and AstraZeneca. Danielle Brander reports grants, non-financial support from AbbVie, ArQule, Ascentage, Astra Zeneca, BeiGene, DTRM, Genentech, Juno/Celgene/BMS, MEI Pharma, Pharmacyclics, Pfizer, Teva, TG Therapeutics, Tolero, Verastem, and memberships with other guidelines/registry memberships (when sponsored or consultant also included under sponsor mentioned): NCCN panel member, informCLL registry steering committee (AbbVie), REAL registry steering committee (Verastem), and Biosimilars outcomes research panel (Pfizer). Bruce Cheson reports personal fees from Abbvie, Pharmacyclics, Celgene, TG Therapeutics, Beigene, AstraZeneca, and Genentech. Paul Barr is consultant for Abbvie, Pharmacyclics, Gilead, Genentech, TG therapeutics, Seattle Genetics, Celgene, Morphosys, Verastem, AstraZeneca, and Janssen. Lindsey Roeker reports family member with minority ownership interest in AbbVie and Abbott Laboratories. Andre Goy reports personal fees from Janssen, Pharmacyclics, during the conduct of the study; as principal investigator for and received funding for institution from Genentech-Hoffman La Roche, including personal fees from Acerta, AstraZeneca, Celgene, Constellation, Infinity, Infinity Verastem, Karyopharm, Kite pharma, Elsevier’s PracticeUpdate Oncology, Gilead, Medscape, MJH Associates, OncLive Peer Exchange, Physcians Education Resource, LLC, Xcenda, and COTA, outside the submitted work. Stephen J Schuster reports personal fees and/or grants from AstraZeneca, Merck, Novartis, Juno/Celgene, Genentech/Roche, Loxo Oncology, Tessa Therapeutics, AlloGene, BeiGene, and Celgene. Dr Nicole Lamanna received research support to institution and advisory board honorarium from Abbvie, Astra Zeneca, Beigene, Genentech, Gilead, Juno, Janssen, Mingsight, Pharmacyclics, TG Therapeutics, Celgene, and Oncternal. Constantine Tam reports personal fees from Abbvie, Janssen, Pharmacyclics. Mazyar Shadman reports personal fees from Abbvie, Genentech, Astra Zeneca, Sound Biologics, Pharmacyclics, Verastem, ADC therapeutics, Beigene, Cellectar, BMS, Mophosys and Atara Biotherapeutics, grants from Mustang Bio, Celgene, Pharmacyclics, Gilead, Genentech, Abbvie, TG therapeutics, Beigene, Astra Zeneca, Sunesis, and Beigene. The authors report no other conflicts of interest in this work.

Figures

Figure 1
Figure 1
Survival by age.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Woyach JA, Ruppert AS, Heerema N, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. doi:10.1056/NEJMoa1812836 - DOI - PMC - PubMed
    1. Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib-rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432–443. doi:10.1056/NEJMoa1817073 - DOI - PMC - PubMed
    1. Hallek M, Cheson BD, Catovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood. 2008;111(12):5446–5456. doi:10.1182/blood-2007-06-093906 - DOI - PMC - PubMed
    1. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53(282):457–481. doi:10.1080/01621459.1958.10501452 - DOI
    1. Anderson P, Gill R. Cox’s regression model for counting processes: a large sample study. Ann Statist. 1982;10(4):1100–1120. doi:10.1214/aos/1176345976 - DOI

LinkOut - more resources